title: Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta.
abstract: DNA polymerases beta (pol beta ) and eta (pol eta ) are the only two eukaryotic polymerases known to efficiently bypass cisplatin and oxaliplatin adducts in vitro. Frameshift errors are an important aspect of mutagenesis. We have compared the types of frameshifts that occur during translesion synthesis past cisplatin and oxaliplatin adducts in vitro by pol beta and pol eta on a template containing multiple runs of nucleotides flanking a single platinum-GG adduct. Translesion synthesis past platinum adducts by pol beta resulted in approximately 50% replication products containing single-base deletions. For both adducts the majority of -1 frameshifts occurred in a TTT sequence 3-5 bp upstream of the DNA lesion. For pol eta, all of the bypass products for both cisplatin and oxaliplatin adducts contained -1 frameshifts in the upstream TTT sequence and most of the products of replication on oxaliplatin-damaged templates had multiple replication errors, both frameshifts and misinsertions. In addition, on platinated templates both polymerases generated replication products 4-8 bp shorter than the full-length products. The majority of short cisplatin-induced products contained an internal deletion which included the adduct. In contrast, the majority of oxaliplatin-induced short products contained a 3' terminal deletion. The implications of these in vitro results for in vivo mutagenesis are discussed.
authors.affiliation: Department of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599-7260, USA.
authors.forename: Ekaterina
authors.initials: E
authors.lastname: Bassett
authors.forename: Alexandra
authors.initials: A
authors.lastname: Vaisman
authors.forename: Kristen A
authors.initials: KA
authors.lastname: Tropea
authors.forename: Chad M
authors.initials: CM
authors.lastname: McCall
authors.forename: Chikahide
authors.initials: C
authors.lastname: Masutani
authors.forename: Fumio
authors.initials: F
authors.lastname: Hanaoka
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Chaney
mesh_terms: D001483:Base Sequence; D002945:Cisplatin / Q000378:metabolism* / Q000494:pharmacology; D018736:DNA Adducts / Q000235:genetics* / Q000378:metabolism*; D004249:DNA Damage; D019951:DNA Polymerase beta / Q000378:metabolism; D004260:DNA Repair; D004259:DNA-Directed DNA Polymerase / Q000378:metabolism; D016368:Frameshift Mutation; D006801:Humans; D066298:In Vitro Techniques; D008954:Models, Biological; D008969:Molecular Sequence Data; D009153:Mutagens / Q000494:pharmacology; D009944:Organoplatinum Compounds / Q000494:pharmacology; D000077150:Oxaliplatin; D011994:Recombinant Proteins / Q000378:metabolism; D017384:Sequence Deletion; D000099270:Y-Family DNA Polymerases
chemical_list: D002945:Cisplatin; D018736:DNA Adducts; D019951:DNA Polymerase beta; D004259:DNA-Directed DNA Polymerase; D009153:Mutagens; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D011994:Recombinant Proteins; C057270:cisplatin-DNA adduct; C112338:Rad30 protein; D000099270:Y-Family DNA Polymerases